Abu Dhabi sovereign wealth fund ADQ is exploring a potential acquisition of Bausch Health Cos.’s Egyptian drug unit, people with knowledge of the matter said. ADQ has been evaluating the Bausch business, known as Amoun Pharmaceutical Co., as it seeks to expand its portfolio of health-care investments, according to the people. Amoun could fetch at least $700m in a sale, the people said, asking not to be identified because the information is private. No final agreements have been reached, and there’s no certainty the deliberations will lead to a transaction, the people said. Amoun could also attract other suitors, according to the people. Representatives for ADQ and Amoun couldn’t immediately comment. A spokesperson for Bausch declined to comment. Bausch, formerly known as Valeant Pharmaceuticals International, has been reshaping its operations since ...read more...